

RECEIVED
CENTRAL FAX CENTER

AUG 30 2007

FAX TRANSMISSION**DATE:** August 30, 2007**PTO IDENTIFIER:** Application Number 10/022,631

Patent Number

Inventor: Mauritius W. GEERLINGS**MESSAGE TO:** US Patent and Trademark Office**FAX NUMBER:** (571) 273-0824**FROM:** WILMER CUTLER PICKERING HALE AND DORR LLP

Jane M. Love, Ph.D.

PHONE: (212) 937-7233**Attorney Dkt. #:** 1000780.120US1**PAGES (Including Cover Sheet):** 6**CONTENTS:** Fee Transmittal (1 page)
Terminal Disclaimer (2 page)
Transmittal (1 page)
Charge \$65.00 to deposit account 08-0219
Certificate of Transmission (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (212) 230-8800 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

WILMER CUTLER PICKERING HALE AND DORR LLP
399 Park Avenue, New York, New York 10022
Telephone: (212) 230-8800 **Facsimile:** (212) 230-8888

RECEIVED
CENTRAL FAX CENTER

AUG 30 2007

PTO/SB/97 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


Application No. (if known): 10/022,631

Attorney Docket No.: 1000780.00120US1

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on August 30, 2007
Date



Signature

Jane M. Love, Ph.D.

Typed or printed name of person signing Certificate

42,812

Registration Number, if applicable

(212) 937-7233

Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Transmittal (1 page)

Fee Transmittal (1 page)

Terminal Disclaimer (2 page)

Charge \$65.00 to deposit account 08-0219

AUG 30 2007

PTO/SB/17 (07-07)

Approved for use through 06/30/2010. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). FEE TRANSMITTAL For FY 2007		Complete if Known Application Number 10/022,631 Filing Date December 17, 2001 First Named Inventor Mauritius W. GEERLINGS Examiner Name L. Y. B. Lum Art Unit 1641 Attorney Docket No. 1000780.120US1	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27			
TOTAL AMOUNT OF PAYMENT (\$) 65.00			

METHOD OF PAYMENT (check all that apply) <input type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> None <input type="checkbox"/> Other (please identify): _____ <input checked="" type="checkbox"/> Deposit Account Deposit Account Number: 08-0219 Deposit Account Name: Wilmer Cutler Pickering Hale and	
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) <input checked="" type="checkbox"/> Charge fee(s) indicated below <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee <input checked="" type="checkbox"/> Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 <input checked="" type="checkbox"/> Credit any overpayments	

FEE CALCULATION 1. BASIC FILING, SEARCH, AND EXAMINATION FEES							
Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	
2. EXCESS CLAIM FEES							
						Small Entity	
Fee Description						Fee (\$)	Fee (\$)
Each claim over 20 (including Reissues)						50	25
Each independent claim over 3 (including Reissues)						200	100
Multiple dependent claims						360	180
Total Claims		Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims		
=		x	=		Fee (\$)		Fee Paid (\$)
HP = highest number of total claims paid for, if greater than 20.							
Indep. Claims		Extra Claims	Fee (\$)	Fee Paid (\$)			
=		x	=				
HP = highest number of independent claims paid for, if greater than 3.							
3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof		Fee (\$)	Fee Paid (\$)		
- 100 =	/50 =	(round up to a whole number) x		=			
4. OTHER FEE(S) Non-English Specification, \$130 fee (no small entity discount) Other (e.g., late filing surcharge): 2814 Statutory Disclaimer 65.00							

SUBMITTED BY Signature <i>Jane M. Love</i> Registration No. 42,812 Telephone (212) 937-7233 Name (Print/Type) Jane M. Love, Ph.D. Date August 30, 2007			
---	--	--	--

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-0824, on the date shown below. Dated: August 30, 2007 Signature: <i>Jane M. Love</i> (Jane M. Love, Ph.D.)	
---	--

6344613
US1DOCS 6344613v1

AUG 30 2007

PTO/SB/21 (04-07)


Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small>	Application Number	10/022,631
	Filing Date	December 17, 2001
	First Named Inventor	Mauritius W. GEERLINGS
	Art Unit	1641
	Examiner Name	L. Y. B. Lum
Total Number of Pages in This Submission	Attorney Docket Number	1000780.120US1

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input checked="" type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	WILMER CUTLER PICKERING HALE AND DORR LLP		
Signature			
Printed name	Jane M. Love, Ph.D.		
Date	August 30, 2007	Reg. No.	42,812

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-0824, on the date shown below.	
Dated: August 30, 2007	Signature: _____ (Jane M. Love, Ph.D.)

RECEIVED
CENTRAL FAX CENTER

AUG 30 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Serial No. : 10/022,631
Applicant : Maurits W. Geerlings
Filed : December 17, 2001
Group Art Unit : 1641
Examiner : Thuy Nguyen
Docket No. : 1000780-120-US1
Customer No. : 28089

Title : METHOD AND MEANS FOR SITE-DIRECTED THERAPY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Terminal Disclaimer

Actinium Pharmaceuticals, Inc. ("Actinium"), the assignee of record of the entire right, title and interest of the subject application by virtue of an Assignment of that was recorded in the United States Patent and Trademark Office on January 22, 2002 at Reel 012548, Frame 0739 from the inventor of the parent application (USSN 09/014,206, now USPN 6,403,771) of the above-identified application, hereby disclaims, except as provided below, the terminal portion of the statutory term of any patent granted on the above-identified patent application, U.S. Serial No. 10/022,631, which would extend beyond the earliest expiration date of the full statutory term defined in 35 U.S.C. §154 to §156 and §173 of U.S. Patent No. 5,641,471 and U.S. Patent No. 6,403,771, and hereby agrees that any patent granted on the subject application shall be enforceable only for and during such period that the legal title to such patent shall be the same as the legal title to the aforementioned patents, this agreement to run with any patent granted on the subject application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, Actinium does not disclaim the terminal part of any patent granted on the subject application that would extend to the expiration date of U.S. Patent No. 5,641,471 and U.S. Patent No. 6,403,771 the full statutory term as defined in 35 U.S.C. §154 to §156 and §173 of in the event that such prior patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims

Page 1 of 2

US1DOCS 6342433v1

09/05/2007 HUONG1 00000135 080219 10022631

01 FC:2814 65.00 DA

canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

I have reviewed the assignment attached hereto and certify that to the best of my knowledge and belief, Actinium, has the entire right, title and interest in the subject application. I further certify that I am authorized to sign this Terminal Disclaimer on behalf of Actinium.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: August 29, 2007

Actinium Pharmaceuticals, Inc.

By: 

Richard Sherman, Esq.
General Counsel
Actinium Pharmaceuticals, Inc.